Related Experiment Video
Updated: Jul 19, 2026
12:55
Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease.
Matthew Mei1, Bo Su, Kristen Harrison
1Department of Pathology, Case Western Reserve University, and MetroHealth Medical Center, Cleveland, Ohio 44106, USA.
Journal of Neurochemistry
|October 27, 2006
Summary
This study reveals increased phosphorylation of Raf-1, a key activator of the extracellular signal-regulated kinase (ERK) pathway, in Alzheimer's disease brains. These findings suggest Raf-1 activation plays a role in Alzheimer's pathogenesis.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathogenesis Research
Background:
- Extracellular signal-regulated kinase (ERK) pathway is crucial for brain function and implicated in Alzheimer's disease (AD).
- Previous studies confirmed ERK activation in AD, but the upstream signaling cascade remained unclear.
- Raf-1 is a key physiological activator of the ERK pathway.
Purpose of the Study:
- To investigate the role of Raf-1, an upstream activator of ERK, in the pathogenesis of Alzheimer's disease.
- To examine the phosphorylation status and localization of Raf-1 in AD brains.
Main Methods:
- Immunocytochemistry and immunoblot analysis were used to detect and quantify phosphorylated Raf-1.
- Co-immunoprecipitation assays were performed to assess interactions between Raf-1, Ras, and MEK1.
- Analysis was conducted on post-mortem brain tissue from AD patients and age-matched controls.
Main Results:
- Phosphorylation at activating (Ser338, Tyr340/341) and inhibitory (Ser259) sites of Raf-1 was significantly increased in Alzheimer's disease brains.
- Specific phospho-epitopes of Raf-1 showed distinct localization patterns, including intracytoplasmic granules and neurofibrillary tangles.
- Increased Raf-1 levels were associated with Ras and MEK1, with overlap observed between phospho-Raf-1 (Ser338) and phospho-Mek1/2.
Conclusions:
- Raf-1 is activated in Alzheimer's disease, indicated by altered phosphorylation patterns.
- The findings suggest a mechanistic link between Raf-1 activation and downstream signaling in AD.
- Activated Raf-1 may mediate Ras-dependent signals contributing to Alzheimer's disease pathogenesis.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:00Enzyme-linked Receptors
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...